UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT ~~REPORT~~REPORTPURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934

~~Pursuant~~Date toof ~~Section~~report ~~13 OR 15~~(d)Date of ~~the~~earliest ~~Securities~~event ~~Exchange~~reported): ~~Act~~June of30, ~~1934~~2017

~~Date~~Medisun ofPrecision ~~Report~~Medicine ~~(Date of earliest event reported): June 6, 2017~~Ltd.

~~Accurexa~~(Exact ~~Inc.~~Name of Registrant as Specified in Charter)

(Exact name of registrant as specified in its charter)


Marshall Islands	000-54907	46-2999657
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Trust Company Complex, Ajeltake Road Majuro, Marshall Islands MH96960
(Address of Principal Executive Offices) (Zip Code) (929) 314-3718
(Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Marshall Islands	000-54907	46-2999657
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Item 5.03 Certificate of Incorporation.

~~Trust~~On ~~Company~~May ~~Complex~~25, ~~Ajeltake~~2017, ~~Road~~Accurexa ~~Majuro,~~Inc. (the "Company") reincorporated and filed Articles of Incorporation (the "Articles of Incorporation") with the Registrar of Corporations of the Marshall Islands ~~MH96960~~effecting a name change of the Company to Medisun Precision Medicine Ltd. and increase in the number of authorized shares of Common Stock to 100,000,000 shares (~~Address~~collectively, ~~including~~the ~~zip~~"Corporate ~~code~~Actions"). The Corporate Actions and the Articles of Incorporation became effective on June 30, 2017, following compliance with notification requirements of ~~principal~~the ~~executive~~Financial ~~offices)~~Industry Regulatory Authority.

~~Registrant’s~~A ~~telephone~~copy of the Certificate of Incorporation is attached hereto as Exhibit 3.1 and incorporated by reference herein. The new CUSIP number, ~~including~~for ~~area~~the ~~code~~Company's ~~(929)~~common ~~314-3718~~stock is Y59514102.

~~N/A~~Item ~~(Former~~5.07 ~~name~~Submission orof ~~former~~Matters ~~address,~~to ifa ~~changed~~Vote ~~since~~of ~~last~~Security ~~report~~Holders.)

~~Check~~The ~~the~~disclosures ~~appropriate~~set ~~box~~forth ~~below~~in ifItem ~~the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A~~5.2.03 ~~below):~~above [are ]incorporated ~~Written~~by ~~communications~~reference ~~pursuant~~into tothis ~~Rule~~Item ~~425 under the Securities Act (17 CFR 230~~5.~~425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240~~07.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~On 1May 15, 2017 (the "Record Date"), the Company obtained written consent by the holder of the majority of the voting power of the Company's capital stock approving the Corporate Actions.01

~~Entry~~Item ~~into~~8.01 aOther ~~Material Definitive Agreement~~Events.

On June 629, 2017, ~~Accurexa Inc. (~~the ~~“Company”)~~Financial ~~entered~~Industry ~~into~~Regulatory aAuthority ~~license agreement~~ (~~“License Agreement”~~FINRA) ~~pursuant~~approved ~~to which Medisun Holdings Limited, a Hong Kong company (“Medisun”) granted~~ the ~~Company~~Corporate aActions. The ~~non-exclusive license (“License”) to use Medisun’~~Company's NKstock ~~(Natural~~is ~~Killer)~~quoted ~~cell~~on ~~technology in~~ the ~~rest~~OTCQB ofunder the ~~world~~ticker ~~(i.e.~~symbol ~~other than the Greater China and the United States~~ACXA, ~~which~~but ~~are~~beginning ~~the~~June ~~licensed regions in the First License Agreement between the Company and Medisun~~30, ~~dated on April 18,~~ 2017 ~~and filed on Form 8-K on May 17~~, ~~2017, as amended) from~~ the date of License until the termination of the First License Agreement (“Term”). Medisun has developed its NK cell technology for the treatment of cancer. The NK cell technology is currently clinically used to treat cancer patients at Medisun’Company's ~~network~~common ~~clinical~~stock ~~facilities.~~began ~~The~~trading ~~License~~under ~~provides that Medisun will provide to~~ the ~~Company~~symbol ~~any relevant technical advice and support from time to time as required by the Company during the Term~~MPME.

AsItem ~~consideration for the License, the Company has agreed to issue to Medisun or its nominees 30,000,000 shares of the Company’s Common Stock~~7.01 ~~These shares were issued pursuant to~~ Regulation DFD ~~under the Securities Act of 1933, as amended (the “Act”), are exempt from registration under Section 4(2) of the Act, and bear an appropriate restrictive legend~~Disclosure.

The ~~foregoing~~ ~~descriptions~~information ~~are~~contained ~~qualified~~ in ~~their~~this ~~entirety~~Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or be otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference ~~to these~~in ~~documents~~any filing under the Securities Act of 1933, ~~which~~as ~~are~~amended, ~~filed~~or ~~herewith~~the Exchange Act, except as ~~Exhibit~~shall ~~10.1~~be ~~and incorporated~~expressly ~~herein~~set forth by specific reference in such a filing.

Item 39.0201 Financial Statement and Exhibits.

~~Unregistered~~(d) ~~Sales of Equity Securities~~Exhibits.

The ~~information~~following ~~set~~documents ~~forth~~are infiled ~~Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.~~herewith:

OnExhibit June 6, 2017, the Company agreed to issue to Medisun Holdings Limited, a Hong Kong corporation, (or its nominees, which is/are its subsidiary(ies)) and an accredited investor, 30,000,000 in shares of its Common Stock as consideration for entering into the License Agreement described in Item 1No.~~01 of this Form 8-K.~~

The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended ("Act"), for the private placement of these securities pursuant to Section 4(2) of the Act since, among other things, the transaction did not involve a public offering, all parties are domiciled outside the United States, and Medisun (and its nominees) is an accredited investor, Medisun had access to information about the Company and its investment, accepted the securities for investment and not resale, and the Company took appropriate measures to restrict the transfer of the securities.Description

~~The form of License Agreement is attached as~~ Exhibit 103.1 ~~to this Form 8-K and is incorporated herein by reference.~~

~~Item~~Certificate ~~9.01~~of Incorporation

~~Financial Statements and Exhibits~~Signatures

~~(d)~~Pursuant ~~Exhibits~~to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

10Medisun Precision Medicine Ltd.1 July 3, 2017 By: /s/ Sophia Yaqi SunSophia Yaqi Sun President and Chief Executive Officer

Form of Licensing Agreement between the Company and Medisun, dated June 6, 2017, and filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ACCUREXA INC.
Dated: June 9, 2017		By: /s/ Sophia Yaqi Sun
		Name: Sophia Yaqi Sun
		Title: President & CEO

Filing Compare · Medisun Precision Medicine Ltd.